中源協和(600645.SH)擬參與設立成都華西細胞治療研究院有限公司
格隆匯1月20日丨中源協和(600645.SH)公佈,隨着全球範圍內細胞治療研究和產業的快速發展,“細胞治療及臨牀轉化”已成為健康產業發展的重要方向和內容。經友好協商,公司決定與成都華西精準醫學產業創新中心有限公司(以下簡稱“華西精準醫學”)、成都華西臨牀研究中心有限公司(以下簡稱“華西臨牀”)共同投資設立成都華西細胞治療研究院有限公司(暫定名,以登記機關核准名稱為準,以下簡稱“華西研究院”),為打造集幹細胞和免疫細胞存儲、檢測、製備、臨牀備案項目申報,以及臨牀轉化應用的高端綜合性細胞資源存儲、研發與轉化應用的一體化產業平台。其中公司出資2250萬元,華西精準醫學出資2250萬元,華西臨牀出資500萬元。
華西研究院的成立,藉助華西醫院的臨牀研究平台,為滿足日益增長的細胞臨牀應用需求,通過整合各方優勢,開展免疫細胞臨牀應用及幹細胞臨牀研究備案項目申報等,實現幹細胞與免疫細胞從規模化儲存到規模化應用,搶先發展先機。同時完善公司在精準治療領域的佈局,有助於提高公司在細胞研發和應用等領域的核心競爭力。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.